Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of PXT3003 in Charcot-Marie-Tooth disease type 1A
MOH_2021-08-15_010195Phase 3Completed
- Sponsor
- Pharnext
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Charcot-Marie-Tooth disease type 1A (CMT1A) comparing PXT3003 with Matching placebo (2 arms). Primary endpoints: Overall Neuropathy Limitations Scale total score and 10-meter walk test. Started Jul 2021; status: completed.
02
Drugs
PXT 3003
03
Conditions
Charcot-Marie-Tooth disease type 1A (CMT1A)
Beyond the preview
Go deeper on MOH_2021-08-15_010195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-08-15_010195.